ArriVent BioPharma, Inc. (AVBP)

17.55 -0.44 (-2.45%) As of 03:43PM EDT. Market open.

ArriVent BioPharma, Inc.

18 Campus Boulevard
Suite 100
Newtown Square, PA 19073
United States
628-277-4836
https://www.arrivent.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 40

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Zhengbin Yao Ph.D.	Co-Founder, Chairman, President & CEO	791.09k	N/A	1966
Dr. Stuart Lutzker M.D., Ph.D.	Co-Founder, President of Research & Development and Director	709.43k	N/A	1961
Ms. Robin LaChapelle M.A.	Co-Founder & COO	586.45k	N/A	1973
Mr. Winston Kung M.B.A.	CFO & Treasurer	N/A	N/A	1976
Ms. Yang Wang Ph.D.	Chief Technology Officer	N/A	N/A	N/A
Mr. James Paul Kastenmayer J.D., Ph.D.	General Counsel & Secretary	N/A	N/A	1972
Dr. Dandan Dong	Chief Business Officer	N/A	N/A	1985
Ms. Meghna Chowdary	Senior Vice President of Commercial Strategy	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Corporate governance

ArriVent BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.